stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Operating cash flow
ACADIA Pharmaceuticals Inc.'s operating cash flow for fiscal 2025 was $109.8M, down 30.4% from $157.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $97.5M. Over the past ten years it has ranged from −$217.8M (fiscal 2017) to $157.7M (fiscal 2024); the current reading is higher than 91% of that period. ACADIA Pharmaceuticals Inc. ranks 29th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $109.8M | (30.36%) |
| FY2024 | $157.7M | 844.31% |
| FY2023 | $16.7M | — |
| FY2022 | −$114.0M | — |
| FY2021 | −$125.7M | — |
| FY2020 | −$136.2M | — |
| FY2019 | −$151.1M | — |
| FY2018 | −$167.5M | — |
| FY2017 | −$217.8M | — |
| FY2016 | −$208.4M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $11.5M | (88.59%) |
| Jun 2026 | $100.8M | 196.58% |
| Mar 2026 | $34.0M | — |
| Dec 2025 | −$48.7M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | $97.5M |
| PBLS Parabilis Medicines, Inc. compare | −$118.1M |
| TNGX Tango Therapeutics, Inc. compare | −$143.9M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$190.0M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| XENE Xenon Pharmaceuticals Inc. compare | −$337.5M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$477.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement